Disc Col

Save items

loading

Similar articles

Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme.[BMJ. 2010]
Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme.
Anttila A, Kotaniemi-Talonen L, Leinonen M, Hakama M, Laurila P, Tarkkanen J, Malila N, Nieminen P. BMJ. 2010 Apr 27; 340:c1804. Epub 2010 Apr 27.
The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.[Health Technol Assess. 2014]
The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J. Health Technol Assess. 2014 Apr; 18(23):1-196.
Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.[J Natl Cancer Inst. 2009]
Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A. J Natl Cancer Inst. 2009 Dec 2; 101(23):1612-23. Epub 2009 Nov 9.
Review Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.[Vaccine. 2008]
Review Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ. Vaccine. 2008 Aug 19; 26 Suppl 10:K29-41.
Review Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.[Vaccine. 2012]
Review Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J. Vaccine. 2012 Nov 20; 30 Suppl 5:F88-99.

See reviews...See all...

Cited by 7 PubMed Central articles

Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56-60.[BMJ Open. 2017]
Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56-60.
Lamin H, Eklund C, Elfström KM, Carlsten-Thor A, Hortlund M, Elfgren K, Törnberg S, Dillner J. BMJ Open. 2017 May 30; 7(5):e014788. Epub 2017 May 30.
High lifetime probability of screen-detected cervical abnormalities.[J Med Screen. 2017]
High lifetime probability of screen-detected cervical abnormalities.
Pankakoski M, Heinävaara S, Sarkeala T, Anttila A. J Med Screen. 2017 Dec; 24(4):201-207. Epub 2017 Jan 10.
Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial.[Br J Cancer. 2016]
Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial.
Coldman AJ, Gondara L, Smith LW, van Niekerk D, Ceballos K, Krajden M, Cook D, Quinlan DJ, Lee M, Stuart GC, et al. Br J Cancer. 2016 Dec 6; 115(12):1487-1494. Epub 2016 Nov 17.

See all...

Related information

Articles frequently viewed together
Articles frequently viewed together
MedGen
Related information in MedGen
References for this PMC Article
References for this PMC Article
Free in PMC
Free full text articles in PMC
Cited in PMC
PubMed links associated with PMC

Recent Activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on